ArticleAMB Express2025
A novel thermostable lytic phage vB_EF_Enf3_CCASU-2024-3 against clinical Enterococcus faecium and Enterococcus faecalis.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Isolation and characterization of a novel lytic bacteriophage vB_EcoS_P78 against multidrug-resistant Escherichia coli.Virus research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterococci, Gram-positive bacteria, have become a major concern in healthcare settings due to their significant virulence and antibiotic resistance. This research focuses on isolating, phenotypic, and genotypic analysis of enterococci-specific lytic phages to be used as potential candidates in combating multidrug-resistant (MDR) Enterococcus clinical isolates. The virulence of Enterococcus isolates was analyzed by testing for gelatinase and biofilm formation. The phage(s) was isolated from a sewage sample, then purified, propagated, and physiochemically analyzed. The phage was examined using transmission electron microscopy, and the whole genome sequence (WGS) was performed. Sixety-five clinical enterococci including, 27 (41.5%), 33 (50.7%) 3 (4.6%), and 2 (3%) E. faecalis, E. faecium, E. avium, and E. durans, respectively were isolated. Linezolid, teicoplanin, chloramphenicol, and vancomycin exhibited the lowest resistance. Twenty-five (38.5%) isolates were both gelatinase- and biofilm-producers. A novel lytic vB_EF_Enf3 phage belonging to Caudoviricetes class, characterized by an icosahedral head with a diameter of 100 ± 5 nm and a tail measuring 70 ± 5 nm in length was isolated. The phage demonstrated good thermal stability, and viability across various pH levels and exhibited a broad- spectrum of activity against E. faecium and E. faecalis. The vB_EF_Enf3 phage (36,202 bp length) harbored 36 open reading frames (ORFs) with a GC content of 34.4% (GenBank accession, PP747318). In conclusion, a novel thermostable lytic bacteriophage vB_EF_Enf3, belonging to class Caudoviricetes, was isolated from sewage showing broad-spectrum potent lytic activity against E. faecium and E. faecalis and maintained stability under various extreme conditions, including temperature, and pH fluctuations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.